IN THE CLAIMS:

PATENT & TRADEMARK COME A C

Please cancel claims 15 and 17.

Please enter the following rewritten claims. A marked up version of the rewritten claims,

MARK WARE a clean version of all pending claims are attached at the end of this document.

4. (Three Times Amended) A kit for diagnosing an autoimmune disease, the kit comprising:

- a first antigen comprising a human HMG-1 polypeptide, a polypeptide having an amino acid sequence homology of 90% or more with human HMG-1 indicated by SEQ ID NO:1, or a fragment thereof which reacts with an antibody from an autoimmune disease patient.
- a second antigen comprising a human HMG-2 polypeptide, a polypeptide having an amino acid sequence homology of 80% or more with human HMG-2 indicated by SEQ ID NO:2, or a fragment thereof which reacts with an antibody from an autoimmune disease patient;
- a first component for detecting a first antigen-antibody complex; and
- a second component for detecting a second antigen-antibody complex; wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, human systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, primary biliary cirrhosis, microscopic polyangitis/polyarteritis nodosa, ulcerative colitis, Chrohn's disease and autoimmune hepatitis.
- (Amended) A diagnostic drug for detecting an antibody of autoimmune diseases, wherein: the drug comprises:
 - a human HMG-1 polypeptide, a polypeptide having an amino acid sequence homology of 90% or more with human HMG-1 indicated by SEQ ID NO:1, or a fragment thereof which reacts with an antibody from an autoimmune disease patient; or
 - a human HMG-2 polypeptide, a polypeptide having an amino acid sequence homology of 80% or more with human HMG-2 indicated by SEQ ID NO:2, or a fragment thereof which reacts with an antibody from an autoimmune disease patient;

the drug reacts with an antibody of an autoimmune disease patient; and

SubE37

14.

12